Back to News
Market Impact: 0.25
Oncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Oncolytics Biotech reported PNAS-published data showing pelareorep treatment was associated with changes in the tumour microenvironment in liver cancer. The clinical-stage biotech announcement provides supportive scientific evidence for the therapy's development, but includes no efficacy, financial, or regulatory milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ONCY0.55
More News
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- Why is Nidec stock plunging today?
- Nidec Corp shares slump after auditor declines to sign off on earnings
- We're raising our Micron price target after an incredible quarter and robust guidance
- Why is Kioxia stock rallying today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund